ADOA Program Update
Open PDF
| Stock | PYC Therapeutics Ltd (PYC.ASX) |
|---|---|
| Release Time | 21 Jul 2026, 8:32 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
PYC Therapeutics Ltd ADOA Program Update
Key Points
- PYC-001 shows sustained gene expression increase in NHPs
- Clinical trial patients show improved visual acuity and reduced stress
- Potential to extend dosing interval in ongoing trials
Full Summary
PYC Therapeutics Ltd has announced positive updates from its ADOA program, highlighting the drug candidate PYC-001. Studies in non-human primates demonstrated a sustained increase in target gene expression in the retina 4 months after a single dose of PYC-001. Additionally, patients in the ongoing Phase 1/2 clinical trials showed sustained improvements in visual acuity and decreased retinal stress. The data supports extending the dosing interval in the clinical trials from every 2-3 months to once every 4 months. The company is also exploring the drug's potential in other blinding eye diseases such as glaucoma.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In